Aquinox Pharmaceuticals Inc. (Nasdaq: AQXP) reported positive results from a
Phase 2 LEADERSHIP trial with AQX-1125 in patients with bladder pain
syndrome/interstitial cystitis. The stock price leaped $8.63 to close at $10.42.
Positive study results for Aquinox Pharmaceuticals
August 07, 2015 at 17:59 PM EDT
